MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences Inc. (PMN)

|||

Cash Flow Overview

Change in Cash
-$10,385,065
Unit: Dollar
Positive Cash Flow Breakdown
    • Accrued liabilities
    • Share-based compensation expense
    • Prepaid expenses and other curre...
    • Accounts payable
Negative Cash Flow Breakdown
    • Net loss
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-11,729,657
-8,244,372
-10,674,088
-11,580,127
Share-based compensation expense
408,894
189,425
203,171
197,147
Change in fair value of financial instruments
-
-
5,592
-
Prepaid expenses and other current assets
-300,242
531,362
-2,993,819
1,059,605
Accounts payable
76,651
-826,591
-1,668,070
1,431,306
Accrued liabilities
558,805
-2,970,620
-131,146
955,654
Net cash used in operating activities
-10,385,065
-12,383,520
-9,281,906
-10,055,625
Purchase of short-term investments
-
-
33,753
-
Maturity of short-term investment
-
-
33,051
-
Net cash used in investing activities
-
-
-702
-
Proceeds from issuance of common shares pursuant to 2025 and 2024 atm offering, respectively, net of issuance costs
-
-
0
708,468
Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs
-
-
-
697,658
Proceeds from issuance of pre-funded warrants from july 22, 2025 registered direct offering, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering
-
-
697,658
-
Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July222025Exercise Of Discounted Warrants And Pipe Offering
-
-
0
8,391,027
Proceeds from issuance of common shares, pre-funded warrants and accompanying common warrants from private placements, net of issuance costs-July282025Exercise Of Discounted Warrants And Pipe Offering
-
-
-1
11,144,468
Proceeds from exercise of pre-funded warrants
-
-
0
3,050
Proceeds from issuance of common shares, pre-funded warrants, and common warrants from january 29, 2026 pipe, net of issuance costs
0
70,081,309
-
-
Net cash provided by financing activities
0
70,081,309
-1
20,944,671
Net increase (decrease) in cash
-10,385,065
57,697,789
-9,282,609
10,889,046
Cash at beginning of period
63,814,345
6,116,556
15,399,165
13,291,167
Cash at end of period
53,429,280
63,814,345
6,116,556
15,399,165
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase(decrease) in cash-$10,385,065 (-18.27%↓ Y/Y)Accrued liabilities$558,805 (-91.49%↓ Y/Y)Share-based compensationexpense$408,894 (-10.59%↓ Y/Y)Prepaid expenses andother current assets-$300,242 (51.64%↑ Y/Y)Accounts payable$76,651 (-92.65%↓ Y/Y)Net cash used inoperating activities-$10,385,065 (-18.27%↓ Y/Y)Canceled cashflow$1,344,592 Net loss-$11,729,657 (32.84%↑ Y/Y)